SGMT SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Denifanstat Advances Through Phase 3 Acne Trials After Positive Chinese Data, With U.S. AURORA Study Underway and Results Expected in 2027

Oct 22, 2026

8-K

Sagimet Biosciences Announces Pricing of Underwritten Offering of Common Stock and Pre-Funded Warrants

Sep 30, 2026

8-K

Sagimet Highlights FASN Inhibitor Pipeline and Denifanstat Clinical Progress in Acne and MASH

Sep 30, 2026

8-K

Sagimet Biosciences Receives FDA Clearance for Phase 3 Clinical Trial of Denifanstat in Acne

Aug 13, 2026

8-K

Sagimet Biosciences Reports Q2 2026 Financial Results and Strategic Focus on Dermatology

Aug 11, 2026

8-K

Sagimet Biosciences Advances Denifanstat and TVB-3567 for Acne and Metabolic Disease

Jul 20, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Sep 30, 2026

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Sep 30, 2026

424B5

REGISTERED OFFERING

Apr 28, 2026

424B5

August 2025 ATM

Aug 14, 2025

424B4

OFFERING | Shares amount: 9,000,000 | Share price: $12.50 | Offering amount: $112,500,000.00

Jan 26, 2024

424B4

OFFERING | Shares amount: 5,312,500 | Share price: $16.00 | Offering amount: $85,000,000.00

Jul 14, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 11, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 11, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 12, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 12, 2025

S-3

SHELF | ATM | Offering amount: $300,000,000.00 EFFECTIVE

Aug 15, 2024

S-8

Registration

Mar 25, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 21, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 18, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 18, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

Commodore Capital LP (Filed by)

Oct 7, 2026

Kemble George (Reporting)

Aug 17, 2026

144

Form 144 - Report of proposed sale of securities

Aug 14, 2026

SCHEDULE 13G

BALYASNY ASSET MANAGEMENT L.P. (Filed by)

Aug 14, 2026

Kemble George (Reporting)

Aug 12, 2026

144

Form 144 - Report of proposed sale of securities

Aug 11, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

May 7, 2025

CORRESP

Form CORRESP - Correspondence

May 5, 2025

LETTER

Form UPLOAD - SEC-generated letter

Apr 22, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 27, 2024

CORRESP

Form CORRESP - Correspondence

Aug 22, 2024

LETTER

Form UPLOAD - SEC-generated letter

Aug 19, 2024

Sagimet Biosciences Inc. SGMT · SEC Filings